Ultragenyx Pharmaceutical Inc.
RARE
Price:
$59.61
Market Cap:
$5.49B
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hyper...[Read more]
Industry
Biotechnology
IPO Date
2014-01-31
Stock Exchange
NASDAQ
Ticker
RARE
The ROE as of September 2024 (TTM) for Ultragenyx Pharmaceutical Inc. (RARE) is -266.02%
According to Ultragenyx Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current ROE is -266.02%. This represents a change of 51.96% compared to the average of -175.06% of the last 4 quarters.
Ultragenyx Pharmaceutical Inc. (RARE) Historical ROE (quarterly & annually)
How has RARE ROE performed in the past?
The mean historical ROE of Ultragenyx Pharmaceutical Inc. over the last ten years is -77.08%. The current -266.02% ROE has changed 245.12% with respect to the historical average. Over the past ten years (40 quarters), RARE's ROE was at its highest in in the March 2018 quarter at 4.18%. The ROE was at its lowest in in the September 2023 quarter at -503.40%.
Average
-77.08%
Median
-50.54%
Minimum
-220.26%
Maximum
-16.16%
Ultragenyx Pharmaceutical Inc. (RARE) ROE by Quarter and Year
Discovering the peaks and valleys of Ultragenyx Pharmaceutical Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 307.79%
Maximum Annual ROE = -16.16%
Minimum Annual Increase = -73.76%
Minimum Annual ROE = -220.26%
| Year | ROE | Change |
|---|---|---|
| 2023 | -220.26% | 9.75% |
| 2022 | -200.69% | 307.79% |
| 2021 | -49.21% | 204.51% |
| 2020 | -16.16% | -73.76% |
| 2019 | -61.60% | 89.81% |
| 2018 | -32.45% | -58.81% |
| 2017 | -78.79% | 51.89% |
| 2016 | -51.87% | 89.20% |
| 2015 | -27.42% | -15.20% |
| 2014 | -32.34% | -53.80% |
Ultragenyx Pharmaceutical Inc. (RARE) Average ROE
How has RARE ROE performed in the past?
The current ROE of Ultragenyx Pharmaceutical Inc. (RARE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-156.72%
5-year avg
-109.59%
10-year avg
-77.08%
Ultragenyx Pharmaceutical Inc. (RARE) ROE vs. Peers
How is RARE’s ROE compared to its peers?
Ultragenyx Pharmaceutical Inc.’s ROE is less than X4 Pharmaceuticals, Inc. (32.93%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than PDS Biotechnology Corporation (-137.06%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Arvinas, Inc. (-55.59%), greater than Revolution Medicines, Inc. (-34.57%), greater than Kura Oncology, Inc. (-40.43%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than Incyte Corporation (2.10%), less than Alnylam Pharmaceuticals, Inc. (47.92%), less than United Therapeutics Corporation (18.82%),
| Company | ROE | Market cap |
|---|---|---|
| 32.93% | $120.16M | |
| -39.58% | $664.66M | |
| -122.70% | $1.21B | |
| -137.06% | $111.93M | |
| -68.93% | $376.72M | |
| -81.10% | $4.12B | |
| -46.15% | $180.76M | |
| -139.02% | $4.35B | |
| -62.63% | $4.33B | |
| -55.59% | $1.74B | |
| -34.57% | $7.38B | |
| -40.43% | $1.60B | |
| -24.63% | $153.20M | |
| 2.10% | $12.77B | |
| 47.92% | $34.69B | |
| 18.82% | $15.32B |
Build a custom stock screener for Ultragenyx Pharmaceutical Inc. (RARE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultragenyx Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Ultragenyx Pharmaceutical Inc. (RARE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Ultragenyx Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Ultragenyx Pharmaceutical Inc.'s ROE?
How is the ROE calculated for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the highest ROE for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the 3-year average ROE for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the 5-year average ROE for Ultragenyx Pharmaceutical Inc. (RARE)?
How does the current ROE for Ultragenyx Pharmaceutical Inc. (RARE) compare to its historical average?